# Radiation Therapy in Combination With Durvalumab for People With Pancreatic Cancer

> **NCT03245541** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 18 (actual)

## Conditions studied

- Pancreatic Adenocarcinoma

## Interventions

- **DRUG:** Durvalumab
- **RADIATION:** Stereotactic Ablative Body Radiotherapy (SABR)

## Key facts

- **NCT ID:** NCT03245541
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-08-14
- **Primary completion:** 2026-09
- **Final completion:** 2026-09
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2025-10-07

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03245541

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03245541, "Radiation Therapy in Combination With Durvalumab for People With Pancreatic Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03245541. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*